Literature DB >> 3987300

Uses and abuses of analysis of covariance in clinical trials.

M J Egger, M L Coleman, J R Ward, J C Reading, H J Williams.   

Abstract

Measurement of improvement in clinical trials in chronic diseases commonly compares baseline data to endpoint values by performing t-tests or analysis of variance (ANOVA) on raw gains or percentage changes. This procedure can be misleading and the use of an analysis of covariance (ANCOVA) should be considered. Properly used, ANCOVA increases statistical power in a clinical trial. However, its advantage over t-tests can be nullified by small numbers of patients, violations of assumptions, and incorrect application of the techniques. An evaluation of ANCOVA in chronic disease studies is given, with examples of its strengths and weaknesses as seen in several drug trials in the rheumatic diseases. Recommendations on its use and a decision tree for the nonstatistician are provided.

Entities:  

Mesh:

Year:  1985        PMID: 3987300     DOI: 10.1016/0197-2456(85)90093-5

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  5 in total

1.  Evaluation of vaccine-induced antibody responses: impact of new technologies.

Authors:  Daniel J Zaccaro; Diane K Wagener; Carol C Whisnant; Herman F Staats
Journal:  Vaccine       Date:  2013-04-11       Impact factor: 3.641

2.  Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.

Authors:  Peter B Gilbert; Alicia Sato; Xiao Sun; Devan V Mehrotra
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

3.  Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study.

Authors:  Bolaji E Egbewale; Martyn Lewis; Julius Sim
Journal:  BMC Med Res Methodol       Date:  2014-04-09       Impact factor: 4.615

4.  Different ways to estimate treatment effects in randomised controlled trials.

Authors:  Twisk J; Bosman L; Hoekstra T; Rijnhart J; Welten M; Heymans M
Journal:  Contemp Clin Trials Commun       Date:  2018-03-28

5.  A novel circRNA-miRNA-mRNA network identifies circ-YOD1 as a biomarker for coronary artery disease.

Authors:  Liu Miao; Rui-Xing Yin; Qing-Hui Zhang; Pei-Juan Liao; Yong Wang; Rong-Jun Nie; Hui Li
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.